

Supplemental Figures for:

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-line Therapy in Patients With Recurrent/Metastatic Head and Neck Cancer Maura L Gillison et al.

Supplemental Figure 1. CONSORT diagram. Assessed for eligibility Enrollment Excluded (n = 145)(N = 506)• Adverse event (n = 5) • Consent withdrawn (n = 18) • Death (n = 7) • No longer met study criteria (n = 108) 2:1 Randomization • Other (n = 7) (N = 361)Allocation Allocated to nivolumab (n = 240) Allocated to investigator's choice (n = 121) Received allocated intervention (n = 236) Received allocated intervention (n = 111) • Did not receive allocated intervention · Did not receive allocated intervention - Patient request to discontinue Patient request to discontinue treatment (n = 1)treatment (n = 2)- No longer met study criteria (n = 2) - Consent withdrawn (n = 6)- Disease progression (n = 1) - No longer met study criteria (n = 2) Discontinued treatment (n = 220) Follow-up Discontinued treatment (n = 110) • Received nivolumab as first-line treatment • Received investigator's choice as first-line for R/M SCCHN and discontinued (n = 44) treatment for R/M SCCHN and discontinued Still on treatment (n = 16)(n = 24)• Received nivolumab as first-line treatment Still on treatment (n = 1)for R/M SCCHN and still on treatment (n = 7)• Received investigator's choice as first-line treatment for R/M SCCHN and still on treatment (n = 1)Analysis Efficacy (n = 240) Efficacy (n = 121) • Randomized to receive nivolumab as • Randomized to receive investigator's choice first-line treatment for R/M SCCHN (n = 52) as first-line treatment for R/M SCCHN (n = 26) Safety (n = 236) Safety (n = 111)

• Received investigator's choice as first-line


treatment for R/M SCCHN (n = 25)

Abbreviations: R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck

· Received nivolumab as first-line treatment

for R/M SCCHN (n = 51)

Supplemental Figure 2. Treatment effect on overall survival by subgroup for the overall intent-to-treat population.



*Stratification factor.

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; Nivo, nivolumab.